top of page

Groups Feed

View groups and posts below.


This post is from a suggested group

shrutika.7971shrutika.7971
shrutika.7971

The Juicer Market was valued at USD 3.08 billion in 2025 and is projected to reach USD 5.76 billion by 2033, growing at a CAGR of 8.15% from 2026 to 2033. The market is witnessing steady expansion driven by rising consumer preference for healthy lifestyles, increasing demand for fresh fruit and vegetable juices, and growing adoption of kitchen appliances that support at-home nutrition and wellness routines.

The increasing awareness of preventive healthcare and dietary habits, combined with rising incidences of obesity, diabetes, and lifestyle-related disorders, is encouraging consumers to shift toward natural beverage consumption. In addition, rapid urbanization, expanding middle-class populations, and growing penetration of modern retail and e-commerce platforms are further accelerating the adoption of juicers across residential households and small commercial food service outlets.


11 Views
Harriet Armstrong
14 hours ago

The growth of the juicer market reflects how many people are paying closer attention to their daily eating habits. I remember comparing kitchen appliances for home use and thinking about which features were genuinely useful rather than just attractive. During that term, I also looked into Java assignment writing help when my coursework became difficult to manage. Market figures can tell us a lot, but changing routines and practical needs also help explain why certain household products become more popular.

This post is from a suggested group

aashish kumar
aashish kumar

The Paradigm Shift in Treating Chronic Gastrointestinal Disorders, Specifically Inflammatory Bowel Disease (IBD), Through the Increasing Adoption and Pipeline Development of Targeted Biologic Therapies

The Gastrointestinal (GI) Drugs Market is currently experiencing a dramatic paradigm shift, most evident in the treatment of chronic inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, driven by the increasing adoption and robust pipeline development of targeted biologic therapies. Historically, the management of IBD relied on non-specific anti-inflammatories, immunosuppressants, and corticosteroids, which often failed to induce deep, sustained remission and were associated with significant systemic side effects. Biologic drugs, a key market driver, represent a class of genetically engineered therapies that target specific components of the inflammatory cascade, such as Tumor Necrosis Factor-alpha (TNF-α), integrins, or interleukins (IL-12/23), offering a mechanism-based approach to control disease activity. These targeted therapies are highly effective in inducing mucosal healing, a key endpoint for long-term prognosis,…


20 Views

This post is from a suggested group

82printshop82printshop
82printshop

Welcome to our group 82 Printing Group! A space for us to connect and share with each other. Start by posting your thoughts, sharing media, or creating a poll.

©2020 by 82 Printing

bottom of page